Core Viewpoint - Eupraxia Pharmaceuticals Inc. reported significant clinical milestones and financial results for Q4 2025, indicating a strong position for future growth and development of its lead program, EP-104GI [2][4]. Financial Performance - The company incurred a net loss of $16.7 million in Q4 2025, compared to a net loss of $7.5 million in Q4 2024, primarily due to increased research and development costs for the EP-104GI program and higher general and administrative expenses [4]. - As of December 31, 2025, Eupraxia had cash reserves of $80.5 million, up from $33.1 million at the end of Q4 2024, which is expected to fund operations into the second half of 2028 [5]. Operational Highlights - Eupraxia achieved key clinical milestones in 2025, including positive follow-up data from the RESOLVE trial for eosinophilic esophagitis (EoE) and the completion of a Phase 2b trial for EP-104IAR [9][12]. - The company anticipates multiple clinical readouts from the ongoing RESOLVE trial and plans to initiate additional clinical programs to expand its pipeline [2]. Technology and Product Development - Eupraxia's proprietary Diffusphere™ technology is designed for optimized local drug delivery, targeting therapeutic areas with high unmet medical needs, including pain and inflammatory gastrointestinal diseases [11]. - The company is developing EP-104GI, which is currently in a Phase 1b/2 trial for EoE, and has plans for further long-acting formulations targeting other inflammatory conditions and oncology [12]. Market and Trade Considerations - Management is monitoring the North American trade situation, particularly the impact of proposed tariffs on imported goods, which could affect the company's operations and costs [6][8]. - Eupraxia manufactures its clinical supplies in the U.S. and maintains U.S. dollar balances to mitigate exchange rate fluctuations [7].

Core Viewpoint - Indivior Pharmaceuticals, Inc. has announced the pricing of a $450 million offering of 0.625% convertible senior notes due 2031, which was increased from an initial offering size of $400 million, with a potential additional $50 million option for initial purchasers [1][4]. Group 1: Offering Details - The notes will be senior, unsecured obligations with an interest rate of 0.625% per annum, payable semi-annually starting September 15, 2026, and maturing on March 15, 2031 [2]. - The initial conversion rate is set at 24.0033 shares of common stock per $1,000 principal amount of notes, translating to an initial conversion price of approximately $41.66 per share, representing a 35% premium over the last reported sale price on March 12, 2026 [2]. - The notes are redeemable at Indivior's option starting March 20, 2029, under certain conditions, including if the stock price exceeds 130% of the conversion price for a specified period [3]. Group 2: Use of Proceeds - Indivior estimates net proceeds from the offering to be approximately $437.7 million, or $486.4 million if the additional notes option is fully exercised [4]. - The company plans to use about $239 million to repay borrowings under its term loan and revolving credit facility, $75 million for repurchasing approximately 2.4 million shares of common stock, and the remainder for general corporate purposes [4][5]. Group 3: Company Background - Indivior is a leader in long-acting injectable treatments for opioid use disorder (OUD), focusing on evidence-based treatment and advancing the understanding of OUD as a chronic but treatable brain disease [8]. - The company has a history of over 25 years in addiction medicine, aiming to help individuals achieve long-term recovery with dignity [8].

Earnings Call InsightsVaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approachMar. 12, 2026 6:53 PM ETVaxart, Inc. (VXRT) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Vaxart (VXRT) Q4 2025 Management View Steven Lo, President and CEO, highlighted several recent milestones, including a partnership with Dynavax for the oral COVID-19 vaccine candidate and the publication of a clinical study data set for the oral norovirus v ...

Financial Data and Key Metrics Changes - Fourth quarter revenues reached $290 million, an increase of 9% year-over-year, with a gross profit percentage of 23%, up four percentage points from the prior year [8][19] - Full year consolidated revenues were $1.069 billion, an increase of $26 million or 2%, with a gross profit percentage of 22%, up from 19% in the previous year [9][24] - GAAP net loss for the fourth quarter was $108 million compared to a net income of $26 million in the fourth quarter of 2024, primarily due to excise tax expenses and a loss on early debt extinguishment [20][25] - Operational EBITDA for the fourth quarter was $22 million, up 144% year-over-year, driven by improved pricing and higher volume [22] Business Line Data and Key Metrics Changes - The AM&C segment saw a revenue increase of 25% in the fourth quarter, attributed to the launch of a direct distribution brand of still films [10] - The print division experienced growth in North America, particularly in the plates division, with the PROSPER 520 moving to full production [11] - Brand licensing continues to grow, contributing significantly to profit and increasing awareness of Kodak, especially in Asia [11] Market Data and Key Metrics Changes - The company reported a strong performance despite global economic and geopolitical uncertainties, with revenue increases across both AM&C and print segments [19] - The film group has seen a resurgence, with several Oscar nominees shot on Kodak film, indicating a positive market response [10] Company Strategy and Development Direction - Kodak's long-term plan remains on track, focusing on growth following a strong 2025, with a commitment to customer-first strategies [5][29] - The company has streamlined operations and reduced operating expenses by over $200 million, positioning itself for future growth [7][8] - Investments in new products and infrastructure are ongoing, with a focus on the pharma division and battery coating technologies [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong balance sheet and operational improvements, which are expected to support future growth [6][29] - The leadership team has undergone significant changes to enhance the company's fundamentals and drive growth [32] Other Important Information - Kodak completed a pension reversion process that generated approximately $1.023 billion, significantly strengthening its balance sheet and reducing ongoing interest expenses [13][14] - The company ended 2025 with $337 million in unrestricted cash, reflecting operational improvements and proceeds from the KRIP settlement [27] Summary of Q&A Session - There was no formal Q&A session during the call, but the investor relations team is available for follow-up inquiries [4]

Runway Growth Finance (NasdaqGS:RWAY) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsCasey Alexander - Senior ResearchDavid Spreng - CEOErik Zwick - Managing DirectorGreg Greifeld - Chief Investment OfficerQuinlan Abel - Assistant VP of Investor RelationsTom Raterman - CFO and COOConference Call ParticipantsRick Shane - Managing Director and Equity Research AnalystSean-Paul Adams - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by, and welcome to the Runway ...

Runway Growth Finance (NasdaqGS:RWAY) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsCasey Alexander - Senior ResearchDavid Spreng - CEOErik Zwick - Managing DirectorGreg Greifeld - Chief Investment OfficerQuinlan Abel - Assistant VP of Investor RelationsTom Raterman - CFO and COOConference Call ParticipantsRick Shane - Managing Director and Equity Research AnalystSean-Paul Adams - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by, and welcome to the Runway ...

Core Viewpoint - The Manitoba Health Coalition and Ontario Health Coalition are responding to the deaths of two paid donors at for-profit plasma collection facilities owned by Grifols, raising concerns about safety and control of the blood system [1]. Group 1: Incident Response - The Coalitions have issued warnings regarding the safety of for-profit plasma collection and the implications for the blood system [1]. - Spokespeople will outline necessary questions and steps to enhance safety and restore confidence in the blood and plasma system following the incident [1]. Group 2: Event Details - A response event is scheduled for March 13 at 10:30 a.m. EDT / 9:30 a.m. CDT via Zoom, with registration required [2]. - Contact information for key representatives from the Manitoba and Ontario Health Coalitions is provided for further inquiries [3].

Core Insights - Indivior Pharmaceuticals is a key player in long-acting injectable treatments for opioid use disorder (OUD), focusing on evidence-based solutions like SUBLOCADE, which is a monthly injectable form of buprenorphine aimed at improving patient outcomes and reducing healthcare costs [1] - A recent study indicates that patients adhering to SUBLOCADE for 12 months experienced a 42% reduction in non-MOUD medical costs, supporting the company's strategy to evaluate OUD treatment based on total healthcare costs [1] Financial Performance - Indivior's stock (INDV) has a price-to-earnings (P/E) ratio of 18, reflecting investor confidence in its earnings potential [2] - The company faces financial challenges, indicated by a negative enterprise value to operating cash flow ratio of -207.20 and a debt-to-equity ratio of -3.58, suggesting potential difficulties in cash flow generation and financial structuring [2] - The current ratio of 0.71 indicates that Indivior may struggle to cover short-term liabilities with its short-term assets [3] Industry Position - Despite financial challenges, Indivior's focus on long-acting injectable treatments and evidence-based care positions it as a leader in addressing OUD, which is recognized as a chronic but treatable brain disease [3]

Financial Data and Key Metrics Changes - In Q4 2025, total investment income was $30 million, and net investment income was $11.6 million, down from $36.7 million and $15.7 million in Q3 2025 respectively [5][16] - The weighted average portfolio risk rating increased to 2.45 in Q4 2025 from 2.42 in Q3 2025 [16] - The total investment portfolio had a fair value of $927.4 million, a decrease of 2% from $946 million in Q3 2025 [16][20] - Net assets decreased to $484.9 million from $489.5 million at the end of Q3 2025 [20] - NAV per share was $13.42 at the end of Q4 2025, down 1% from $13.55 at the end of Q3 2025 [20] Business Line Data and Key Metrics Changes - The company completed 7 investments in new and existing portfolio companies totaling $42.9 million in Q4 2025 [5][14] - Notable investments included a $20 million investment in a mobility company and a $10 million investment in a special purpose vehicle for consumer products [14] Market Data and Key Metrics Changes - The company noted ongoing market volatility due to tariff uncertainty, interest rate policy changes, and geopolitical conflicts, impacting investment strategies [6] - The competitive landscape in software and consumer sectors is providing attractive returns, despite the company maintaining a conservative underwriting approach [30] Company Strategy and Development Direction - The company is focused on enhancing the risk profile of its portfolio through diversification and smaller position sizes [6] - The acquisition of SWK Holdings is expected to diversify the portfolio and strengthen capabilities in healthcare and life sciences [7][8] - The company aims to maintain a leverage ratio between 1.2 and 1.3 post-acquisition, considering economic conditions [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in closing the SWK transaction, which is anticipated to stabilize the asset base and enhance earnings power [18][23] - The company expects to see attractive opportunities across technology, healthcare, and consumer sectors in the coming quarters [8][15] Other Important Information - Total operating expenses for Q4 2025 were $18.4 million, down from $21 million in Q3 2025 [19] - The company recorded a net realized loss on investments of $377 thousand in Q4 2025, compared to a loss of $1.3 million in Q3 2025 [19] Q&A Session Summary Question: Pipeline strength and industry focus - Management noted that the pipeline is stronger than the previous year, with significant contributions from BC Partners and SWK, indicating a positive outlook for new deals [29][30] Question: Pro forma leverage post-acquisition - The pro forma leverage post-SWK acquisition is expected to be just under 1.2, with a target range of 1.2 to 1.3 moving forward [34] Question: Updates on SWK Holdings portfolio - The SWK portfolio is expected to include 13 loans with a fair value of around $235 million, alongside equity positions [40] Question: Software portfolio performance - Management confirmed that Circadence has closed an equity round and signed a contract with the Department of Defense, indicating improved performance [43] Question: Share repurchase program - The company plans to revisit the share repurchase program post-acquisition, with discussions expected in May [51][52]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that during the Class Period, Corcept's defendants misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval [5]. - Defendants communicated confidence in the NDA submission and indicated no anticipated obstacles to approval, despite the FDA raising concerns about the clinical evidence [5]. - The lawsuit claims that when the true situation regarding the NDA was revealed, investors suffered damages due to the misrepresentation [5].